Benzochloroporphyrin derivative photosensitizer-mediated photodynamic therapy for Ewing sarcoma

• The photosensitivity of BCPD-18 on Ewing Sarcoma has been tested both in vitro and in vivo.
• Apoptosis and cell cycle arrest were detected after BCPD-18 mediated PDT.
• Expression of Bax increased while expression of Bcl-2 decreased after in vivo BCPD-18 mediated PDT.

In this study, we evaluated the photodynamic efficacy of a new photosensitizer, benzochloroporphyrin derivative 18 (BCPD-18), in Ewing sarcoma. We found that BCPD-18 decreased the viability of TC-71 cells irradiated by 670 nm laser in a concentration dependent manner. We also observed cells undergoing apoptosis as well as cell cycle arrest at the G2M phase after BCPD–18-mediated photodynamic therapy (BCPD-PDT). In addition, in vivo study (subcutaneous and orthotopic models) showed that BCPD-PDT reduced tumor size, tumor weight and tumor-bearing leg weight. After PDT, apoptosis was shown in vivo. Bax expression was increased, and Bcl-2 expression was decreased. This study provides evidence that BCPD-18 could probably be a useful photosensitizer in PDT for Ewing sarcoma.

Figure optionsDownload as PowerPoint slide